| 言語 |
英語
|
| 著者 |
Sakurai, Yuuichi
Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
Takabayashi, Nobuyoshi
Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
Kudou, Kentaro
Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
Araki, Takahiro
Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
Miyagi, Takuya
Department of Internal Medicine, Fukuyama Daiichi Hospital, Hiroshima, Japan
Iwakiri, Katsuhiko
Department of Gastroenterology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Ashida, Kiyoshi
Department of Gastroenterology, Rakuwakai Otowa Hospital, Kyoto, Japan.
|
| 掲載誌名 |
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
|
| 巻 | 10
|
| ISSN | 2155-384X
|
| 発行日 | 2019-11
|
| DOI | |
| PubMed ID | |
| 出版者 | LIPPINCOTT WILLIAMS & WILKINS
|
| 資料タイプ |
学術雑誌論文
|
| 部局 |
医学部
|
| 備考 | This study was sponsored by Takeda Pharmaceutical Company Limited, manufacturer/licensee of Takecab or Vocinti. Takeda Pharmaceutical Company Limited was involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Thao Le, MD, PhD, and Tania Dickson, PhD, CMPP, of ProScribe-Envision Pharma Group and was funded by Takeda Pharmaceutical Company Limited. ProScribe's services complied with international guidelines for Good Publication Practice (GPP3). Ethical approval and informed consent: The study was registered (ClinicalTrials.gov: NCT02954848), approved by the local institutional review board, and conducted at 44 study sites in Japan in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guideline for Good Clinical Practice, and applicable Japanese regulations. All patients signed the informed consent form before participation.
|
